Lilly Insulin Glargine Versus Lantus ® in Insulin-Naïve and Insulin-Treated Adults with Type 2 Diabetes: A Randomized, Controlled Trial (ELEMENT 5)

ConclusionOverall, LY IGlar and IGlar combined with OAMs provided similar glucose control and safety findings in this T2D population, which included a greater proportion of Asian patients and had broader background basal insulin experience than a previously studied T2D population.Trial RegistrationClinicalTrials.gov identifier, NCT02302716.FundingEli Lilly and Company and Boehringer Ingelheim.Plain Language SummaryPlain language summary available for this article.

http://link.springer.com/10.1007/s13300-018-0549-3

Source: Diabetes Therapy - January 2, 2019 Category: Endocrinology Source Type: research